OtherCardiovascular
ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a Novel Non-peptide Delta Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects
Michael J. Watson, Jonathon D. S. Holt, Scott J. O'Neill, Ke Wei, William Pendergast, Garrett J. Gross, Peter J. Gengo and Kwen-Jen Chang
Journal of Pharmacology and Experimental Therapeutics September 27, 2005, DOI: https://doi.org/10.1124/jpet.105.092742
Michael J. Watson
Jonathon D. S. Holt
Scott J. O'Neill
Ke Wei
William Pendergast
Garrett J. Gross
Peter J. Gengo

This is a PDF-only article. The first page of the PDF of this article appears below.

In this issue
OtherCardiovascular
ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a Novel Non-peptide Delta Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects
Michael J. Watson, Jonathon D. S. Holt, Scott J. O'Neill, Ke Wei, William Pendergast, Garrett J. Gross, Peter J. Gengo and Kwen-Jen Chang
Journal of Pharmacology and Experimental Therapeutics September 27, 2005, DOI: https://doi.org/10.1124/jpet.105.092742
OtherCardiovascular
ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a Novel Non-peptide Delta Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects
Michael J. Watson, Jonathon D. S. Holt, Scott J. O'Neill, Ke Wei, William Pendergast, Garrett J. Gross, Peter J. Gengo and Kwen-Jen Chang
Journal of Pharmacology and Experimental Therapeutics September 27, 2005, DOI: https://doi.org/10.1124/jpet.105.092742